KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Abbott Laboratories (ABT) Cost of Revenue (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Cost of Revenue for 17 consecutive years, with $4.9 billion as the latest value for Q4 2025.

  • Quarterly Cost of Revenue changed 0.4% to $4.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.3 billion through Dec 2025, up 3.28% year-over-year, with the annual reading at $19.3 billion for FY2025, 3.28% up from the prior year.
  • Cost of Revenue hit $4.9 billion in Q4 2025 for Abbott Laboratories, down from $5.1 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $5.1 billion in Q3 2025 to a low of $4.3 billion in Q1 2023.
  • Historically, Cost of Revenue has averaged $4.7 billion across 5 years, with a median of $4.6 billion in 2022.
  • Biggest five-year swings in Cost of Revenue: surged 51.61% in 2021 and later fell 13.15% in 2023.
  • Year by year, Cost of Revenue stood at $4.8 billion in 2021, then decreased by 3.63% to $4.6 billion in 2022, then decreased by 0.81% to $4.6 billion in 2023, then increased by 8.47% to $4.9 billion in 2024, then fell by 0.4% to $4.9 billion in 2025.
  • Business Quant data shows Cost of Revenue for ABT at $4.9 billion in Q4 2025, $5.1 billion in Q3 2025, and $4.9 billion in Q2 2025.